Placebo-controlled single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of BMS-650032 in subjects chronically infected with hepatitis C virus genotype 1

Trial Profile

Placebo-controlled single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of BMS-650032 in subjects chronically infected with hepatitis C virus genotype 1

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2009

At a glance

  • Drugs Asunaprevir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Nov 2009 Results presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2009).
    • 28 Sep 2008 Planned number of patients changed from 91 to 24 as reported by CT.gov
    • 28 Sep 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top